Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: Patient-reported outcomes from a phase III trial

Arthritis Care and Research

Volumn 67, Issue 4, 2015, Pages 475-483

  Strand, Vibeke ^a   Burmester, Gerd R ^b   Zerbini, Cristiano A F ^c   Mebus, Charles A ^d   Zwillich, Samuel H ^d   Gruben, David ^d   Wallenstein, Gene V ^d  

^a Biopharmaceutical Consultant   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Centro Paulista de Investigacao Clinica   (Brazil)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PLACEBO; TOFACITINIB; ANTIRHEUMATIC AGENT; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ACUTE DISEASE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE; GLOBAL ASSESSMENT OF DISEASE ACTIVITY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL OUTCOMES STUDY; PAIN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SELF REPORT; SHORT FORM 36; TREATMENT OUTCOME; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PIPERIDINES; PYRIMIDINES; PYRROLES; SELF REPORT; TREATMENT OUTCOME;

EID: 84925443908     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22453     Document Type: Article

References (42)

1. Strand V, Singh JA,. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010; 70: 121-45.
2. Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D,. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol 2012; 39: 63-72.
3. Strand V, Smolen JS, van Vollenhoven RF, Mease P, Burmester GR, Hiepe F, et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis 2011; 70: 996-1002.
4. Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D, et al. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005; 53: 697-702.
5. Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 2007; 34: 1174-7.
6. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40.
7. Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadelo S, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009; 68: 1680-5.
8. Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis: progress at OMERACT 7. J Rheumatol 2005; 32: 2250-6.
9. Kirwan JR, Tugwell PS,. Overview of the patient perspective at OMERACT 10: conceptualizing methods for developing patient-reported outcomes. J Rheumatol 2011; 38: 1699-701.
10. Pincus T,. Are patient questionnaire scores as "scientific" as laboratory tests for rheumatology clinical care? Bull NYU Hosp Jt Dis 2010; 68: 130-9.
11. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
12. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
13. Lipsky PE, van der Heijde DM, St.Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
14. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
15. Chatzidionysiou K, van Vollenhoven RF,. When to initiate and discontinue biologic treatments for rheumatoid arthritis? J Intern Med 2011; 269: 614-25.
16. Aletaha D, Strand V, Smolen JS, Ward MM,. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008; 67: 238-43.
17. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-60.
18. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507.
19. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013; 159: 253-61.
20. Van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65: 559-70.
21. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-19.
22. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370: 2377-86.
23. Strand V, van der Heijde D, Zerbini CA, Connell CA, Gruben D, Riese R, et al. ORAL SCAN: effects of the oral JAK inhibitor tofacitinib in combination with methotrexate on patient reported outcomes in a 24-month phase 3 trial of active rheumatoid arthritis [abstract]. Arthritis Rheum 2013; 65 Suppl 10: S996.
24. Strand V, Fleischmann R, Alten R, Koncz T, Zwillich SH, Bradley JD, et al. Oral START: effects of the oral JAK inhibitor tofacitinib monotherapy versus methotrexate on patient reported outcomes in the phase 3 Oral START Trial of Active Rheumatoid Arthritis [abstract]. Ann Rheum Dis 2013; 72 Suppl 3: 252-3.
25. Burmester GR, van der Heijde D, Strand V, Zerbini CA, Connell CA, Mebus CA, et al. Effects of tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis receiving stable-dose methotrexate: results of two phase 3 studies [abstract]. Arthritis Rheum 2012; 64 Suppl 10: 549.
26. Van Vollenhoven RF, Wallenstein G, Lee EB, Fleischmann R, Zwillich S, Gruben D, et al. Effects of tofacitinib (CP-690,550), an oral janus kinase inhibitor, or adalimumab on patient reported outcomes in a phase 3 study of active rheumatoid arthritis [abstract]. Ann Rheum Dis 2012; 71 Suppl 3: 206.
27. Strand V, Kremer JM, Li ZG, Hall S, Fleischmann RM, Genovese MC, et al. Tofacitinib (CP-690,550) in combination with traditional disease-modifying anti-rheumatic drugs: phase 3 study patient-reported outcomes in patients with active rheumatoid arthritis and an inadequate response to disease-modifying anti-rheumatic drugs. Arthritis Rheum 2011; 63: S1032.
28. Strand V, Kanik K, Connell CA, Fleischmann R, Kremer J, Bradley J, et al. The effects of the oral JAK inhibitor CP-690,550 on patient reported outcomes in a phase 3 study of active rheumatoid arthritis [abstract]. Ann Rheum Dis 2011; 70 Suppl 3: 88-9.
29. Fries JF, Spitz PW, Young DY,. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9: 789-93.
30. Ware JE, Kosinski M, Dewey JE,. How to score version two of the SF 36 Health Survey. Lincoln, RI: Quality Metric; 2000.
31. Strand V, Crawford B, Singh J, Choy E, Smolen JS, Khanna D,. Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis 2009; 68: 1800-4.
32. Cella D, Lai JS, Chang CH, Peterman A, Slavin M,. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002; 94: 528-38.
33. Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, et al. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005; 32: 590-601.
34. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA,. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 557-60.
35. Strand V, Bombardier C, Maetzel A, Scott D,. Use of minimum clinically important differences (MCID) in evaluating patient responses to treatment of rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001; 44 Suppl: S187.
36. Wells G, Li T, Maxwell L, Maclean R, Tugwell P,. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 2008; 67: 260-5.
37. Strand V, Mease P, Burmester GR, Nikai E, Coteur G, van Vollenhoven R, et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther 2009; 11: R170.
38. Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2008; 59: 785-93.
39. Strand V, Burmester GR, Ogale S, Devenport J, John A, Emery P,. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford) 2012; 51: 1860-9.
40. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353: 1114-23.
41. Burmester G, Blanco R, Rubbert-Roth A, Hendrikx T, Kwok K, Bradley J, et al. Short- and long-term efficacy of tofacitinib, an oral Janus kinase inhibitor, in the treatment of patients with rheumatoid arthritis and an inadequate response to TNF inhibitors: analyses of pooled phase 2, phase 3, and long-term extension studies [abstract]. Arthritis Rheum 2012; 64: 4172.
42. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014; 41: 837-52.